Severe ascites: Efficacy of the transjugular intrahepatic portosystemic shunt in treatment

被引:66
作者
Crenshaw, WB
Gordon, FD
McEniff, NJ
Perry, LJ
Hartnell, G
Anastopoulos, H
Jenkins, RL
Lewis, WD
Wheeler, HG
Clouse, ME
机构
[1] DEACONESS HOSP,DEPT RADIOL SCI,BOSTON,MA
[2] DEACONESS HOSP,DEPT MED,BOSTON,MA
[3] DEACONESS HOSP,DEPT HEPATOBILIARY SURG,BOSTON,MA
[4] HARVARD UNIV,SCH MED,BOSTON,MA
关键词
hepatic veins; liver; cirrhosis; interventional procedure;
D O I
10.1148/radiology.200.1.8657908
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: To evaluate the transjugular intrahepatic portosystemic shunt (TIPS) as primary treatment in patients with cirrhosis and severe ascites. MATERIALS AND METHODS: A TIPS placement was attempted in 54 consecutive patients with intractable ascites. Clinical assessment findings, shunt patency, complications, and survival were analyzed. RESULTS: A TIPS was successfully placed in 50 patients (93%). Follow-up for clinical effectiveness in 51 patients was a mean of 285 days (range, 1-981 days). Forty patients (78%) gained clinical benefit from the shunt Of these, 29 (57%) had a complete response (required no further paracentesis) and 11 patients (22%) had a partial response (required less frequent but additional paracentesis for control of ascites). The absence of preprocedure renal insufficiency (creatinine < 1.5 mg/dL [< 130 mu mol/L]) was the only characteristic identified as an indicator of clinical success (P <.05). Eleven patients (22%) required shunt revision during follow-up to gain or prolong control of symptoms. Cumulative survival in the population evaluated for clinical efficacy was 53% at 6 months and 48% at 1 year. A complete response was the only variable that indicated increased survival (P <.05; R(2) = 12%) with a 6-month survival rate of 76% and a 1-year rate of 71%. CONCLUSION: TIPS placement appears to be effective as a primary treatment of patients with cirrhosis and severe ascites.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 44 条
[1]  
ALMADAL TP, 1987, SCAND J GASTROENTERO, V22, P295
[2]   MANAGEMENT OF PATIENTS WITH CIRRHOSIS AND ASCITES [J].
ARROYO, V ;
GINES, P ;
PLANAS, R ;
PANES, J ;
RODES, J .
SEMINARS IN LIVER DISEASE, 1986, 6 (04) :353-369
[3]  
Arroyo V, 1989, GASTROENTEROL INT, V2, P195
[4]   THE TREATMENT OF REFRACTORY ASCITES BY THE LEVEEN SHUNT - A MULTICENTER CONTROLLED TRIAL (57 PATIENTS) [J].
BORIES, P ;
COMPEAN, DG ;
MICHEL, H ;
BOUREL, M ;
CAPRON, JP ;
GAUTHIER, A ;
LAFON, J ;
LEVY, VG ;
PASCAL, JP ;
QUINTON, A ;
TOUMIEUX, B ;
WEILL, JP .
JOURNAL OF HEPATOLOGY, 1986, 3 (02) :212-218
[5]   INFLUENCE OF HEPATIC RESERVE AND CAUSE OF ESOPHAGEAL-VARICES ON SURVIVAL AND REBLEEDING BEFORE AND AFTER THE INTRODUCTION OF SCLEROTHERAPY - A RETROSPECTIVE ANALYSIS [J].
DIMAGNO, EP ;
ZINSMEISTER, AR ;
LARSON, DE ;
VIGGIANO, TR ;
CLAIN, JE ;
LAUGHLIN, BL ;
HUGHES, RW .
MAYO CLINIC PROCEEDINGS, 1985, 60 (03) :149-157
[6]   REFRACTORY ASCITES - EARLY EXPERIENCE IN TREATMENT WITH TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT [J].
FERRAL, H ;
BJARNASON, H ;
WEGRYN, SA ;
RENGEL, GJ ;
NAZARIAN, GK ;
RANK, JM ;
TADAVARTHY, SM ;
HUNTER, DW ;
CASTANEDAZUNIGA, WR .
RADIOLOGY, 1993, 189 (03) :795-801
[7]  
FOSCHAGER MC, 1995, AJR, V165, P1
[8]  
FRANCO D, 1988, ARCH SURG-CHICAGO, V123, P987
[9]  
FULENWIDER JT, 1986, ARCH SURG-CHICAGO, V121, P351
[10]   RANDOMIZED COMPARATIVE-STUDY OF THERAPEUTIC PARACENTESIS WITH AND WITHOUT INTRAVENOUS ALBUMIN IN CIRRHOSIS [J].
GINES, P ;
TITO, L ;
ARROYO, V ;
PLANAS, R ;
PANES, J ;
VIVER, J ;
TORRES, M ;
HUMBERT, P ;
RIMOLA, A ;
LLACH, J ;
BADALAMENTI, S ;
JIMENEZ, W ;
GAYA, J ;
RODES, J .
GASTROENTEROLOGY, 1988, 94 (06) :1493-1502